BARDA

Today, there are no @US_FDA-approved broad-spectrum therapeutics to treat people with dengue, Zika, West Nile, and Chikungunya and other diseases caused by members of these viral families – but we’re working to change that. BARDA and VITAL, a BARDA Accelerator Network Hub, are partnering to offer prizes to the innovators who can develop novel broad-spectrum antiviral drugs that address this gap in the antiviral pipeline. aspr.hhs.gov/newsroom/Pages…

Together with @CompMedUCLA, we're furthering development of the SwabSeq Metagenomic Diagnostic Platform, designed to detect viral pathogens. It could serve as a rapid response tool to detect a novel respiratory virus in a #HealthSecurity emergency: medicalcountermeasures.gov/barda/dddi

We’re partnering with VITAL, a BARDA Accelerator Network Hub, to administer the SMART Antiviral Prize, a new $100 million prize competition aimed at advancing the development of novel, broad-spectrum, antiviral drugs. Launching in 2026. Get the details: vitalhubhealth.com/antiviral-priz…

Procuring #MedicalCountermeasures that are FDA-approved, licensed, and cleared can help ensure their availability in future health security emergencies. See more in our #CBRN portfolio here: medicalcountermeasures.gov/barda/cbrn

BARDA is bolstering national preparedness through the procurement of multiple #MedicalCountermeasures needed to protect the U.S. population from chemical, biological, radiological, and nuclear (#CBRN) threats.

Treatment courses of the oral suspension of @US_FDA-approved smallpox antiviral TEMBEXA (brincidofovir). This formulation fills a key preparedness gap for patients of all ages who are unable to swallow tablets.

Additional treatment courses of @Amgen’s Nplate, an @US_FDA-approved drug to treat the effects of acute radiation syndrome after a nuclear detonation. Amgen will maintain the product in vendor managed inventory for use in future emergencies.

@FluGenInc @OsivaxVaccines Current flu vaccines, while effective, may not address all variants that could emerge during an influenza pandemic. Therefore, broad-acting vaccines like these could protect against multiple strains and help bolster pandemic preparedness: medicalcountermeasures.gov/barda/influenz…

We’re partnering with @FluGenInc and @OsivaxVaccines to develop innovative #influenza vaccines, which could be used to address both pandemic and seasonal flu. If successful, these vaccines could help bolster national pandemic preparedness efforts.

@FluGenInc @OsivaxVaccines @OsivaxVaccines is developing OVX836, a next-generation, broad-spectrum vaccine. It is designed to provide long-lasting protection against both seasonal and pandemic #influenza A strains, allowing for a universal approach to vaccination during a flu pandemic.

@FluGenInc @OsivaxVaccines @FluGenInc is developing a novel, live-attenuated vaccine candidate that is administered intranasally. This effort could help identify Correlates of Protection biomarkers that may streamline the development pathway for further research and development.

In partnership w/ @CidaraThera, we're developing CD388, a long-acting, antiviral prophylactic for pandemic use. CD388 could protect against seasonal & pandemic #influenza infections when a vaccine is not available or for individuals who can’t receive or don’t respond to vaccines.

Innovators and product developers: Meet with BARDA leaders in San Francisco January 12-15. Act now to request a meeting to discuss your #HealthSecurity technologies and medical countermeasures, and learn about potential funding opportunities: ow.ly/IPZi50XSCTx

Innovators and product developers: Meet with BARDA leaders in San Francisco January 12-15. Act now to request a meeting to discuss your #HealthSecurity technologies and medical countermeasures, and learn about potential funding opportunities: ow.ly/IPZi50XSCTx

Innovators and product developers: Meet with BARDA leaders in San Francisco January 12-15. Act now to request a meeting to discuss your #HealthSecurity technologies and medical countermeasures, and learn about potential funding opportunities: ow.ly/uCnB50XSowX

We’re partnering with VITAL, a BARDA Accelerator Network Hub, to administer the SMART Antiviral Prize, a new $100 million prize competition aimed at advancing the development of novel, broad-spectrum, antiviral drugs. Launching in 2026. Get the details: vitalhubhealth.com/antiviral-priz…

We’re partnering with VITAL, a BARDA Accelerator Network Hub, to administer the SMART Antiviral Prize, a new $100 million prize competition aimed at advancing the development of novel, broad-spectrum, antiviral drugs. Launching in 2026. Get the details: vitalhubhealth.com/antiviral-priz…

BARDA is partnering with @Orexo US, Inc., a part of @OrexoABpubl, to develop Orexo OX390, a rescue nasal powder for overdoses involving illicit drugs of concern often mixed with fentanyl. See more in our portfolio: medicalcountermeasures.gov/barda/cbrn

We’re developing an OTC, single-use, digitally connectable antigen test with Sapphiros to detect and differentiate between respiratory viruses. If @US_FDA-cleared, it will be the first-to-market, OTC digital-read test for respiratory infectious diseases: ow.ly/YKEO50XA9LO